An Interim analysis of 18 patients, completing 24/25 weeks of treatment in a phase 2 study in complement-naïve PNH patients demonstrates that KP104 is safe, well-tolerated, and has successfully met all primary and secondary endpoints. KP104 effectively managed both intravascular and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.